Stoke Therapeutics STOK 深 沪
等待开盘 08-28 09:30:00 美东时间
32.59
-0.500
-1.51%
华盛通- 最 高33.18
- 今 开33.01
- 成交量 93.93万股
- 最 低 32.0005
- 昨 收 33.09
- 总市值 21.03亿
- 52周最高 40.22
- 市盈率 静 --
- 换手率 1.46%
- 52周最低 20.32
- 委 比 99.82%
- 总股本 6452.62万
- 历史最高 71.58
- 量 比 0.90
- 振 幅 3.56%
- 历史最低 3.35
- 每 手 1
- 风险率 3.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.
08-22 03:06
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
Stoke Therapeutics Charts Path From EMPEROR To Launch
Stoke Therapeutics (($STOK)) has held its Q2 earnings call. Read on for the mai...
08-05 08:58
Stoke Therapeutics Files Prospectus For Up To $200M ATM Stock Offering; Replaces Prior Program After Selling 4.7M Shares For $146.4M In Net Proceeds
Up to $200,000,000 Common Stock We previously entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock offered by this prospectus supplement and the accompanying base prospectus. In accordance...
08-04 05:07
Stoke Therapeutics Q2 EPS $(0.93) Misses $(0.80) Estimate, Sales $9.325M Beat $6.044M Estimate
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.80) by 16.25 percent. This is a 132.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $9.325 mi...
08-04 04:02
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Stoke Therapeutics任命Thomas McCauley博士为首席科学官
生物技术公司Stoke Therapeutics近日宣布，任命Thomas McCauley博士为首席科学官，负责领导公司的科学战略，并推动其基于RNA药物...
07-13 20:49
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44
Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $44.
07-13 17:43
